Store it upright, away from the freezer compartment and door shelves where temperature fluctuates most
Cardiologists treating patients with atherosclerotic cardiovascular disease are increasingly initiating semaglutide as a cardiovascular risk modifier, adding an estimated 4.8 million new commercial GLP-1 patients annually
Additional enforcement actions are active and ongoing, and we will not hesitate to take strong action to protect patients and consumers," Tong added
Ask your doctor or pharmacist about current program availability, as terms change frequently
Orforgliprons application as a type 2 diabetes treatment will be filed with the FDA later this year
Benefits Significant, clinically proven weight loss Reduced risk of Type 2 diabetes, high blood pressure, and cardiovascular disease Non-surgical, once-weekly injection Personalized dosing not a one-size-fits-all approach Physician-supervised by a board-certified plastic surgeon Built-in path to body contouring if needed after weight loss Best candidates for GLP-1 weight loss injections GLP-1 type medications are suitable for adults who: Have a body mass index (BMI) of 30 or higher (obesity) Have a BMI of 27 or higher (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, or high cholesterol
